TWST Twist Bioscience Corporation
TWST Twist Bioscience Corporation
Healthcare · Diagnostics & Research
Desk view
Market read
Scan convergence 1 scan as of 2026-08-17 1 bull converging
POC $29.74 · VWAP $51.93 · +139.6% vs 12m avg buyer
Insiders no data — outside the Form 4 poll — US-filer feed only (foreign filers report via MAR managers'-transactions notices)
Coverage
2 watchlists
TWST Price Structure
Loading timeframes…
Peers
Every watchlist TWST belongs to, members best 30-day change first — TWST highlighted in place. Each pill: 30d change, 1d/7d, and a close spark over the last 30 calendar days (~21 sessions); hover for price, RSI, and the full chart.
@biotech-capital-cycle
@ibb
Decision history
1 scored call · newest first · projection
How to read this: Positive 30-day excess supports an enter call. For pass, avoid, sell, or exit calls, a positive number means the name kept rising after the call.
Reported the quarter ending 2026-03-31: revenue $111M, diluted EPS $-0.71, net income $-44M (SEC filing). Across the print the stock moved -6.1% (close before → first close after).
full note →Against street estimates
How TWST's reported EPS compared with analyst consensus. Street estimates are single-source vendor consensus (yfinance). Actuals are vendor consensus-basis EPS (often non-GAAP); edgarEps is GAAP diluted from filings — disputed flags large disagreement only. EPS only.
News (last pull)
Headlines about TWST from the desk's news pull — links go to the publisher. Not a desk read: the market read above is the desk's own.
pulled 111 days ago · Apr 29 · last pull reported an error, so these may be older than they look
TWST research tape
29 dated scans, research, and events, newest first — the full record. Desk commentary and scheduled prints sit in their own panes.
Desk commentary
Authored analysis and challenge notes tied to TWST.
Vertical: Biotech Capital Cycle — the theme is confirmed; the question is now entries